Compare ThredUp Inc (TDUP) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ThredUp Inc vs Twist Bioscience Corp — how do they compare? ThredUp Inc trades at $2.73 (market cap $350.00M), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is far larger — about 24.1× ThredUp Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals.
| TDUP | TWST | |
|---|---|---|
Market Cap | $350.00M | $8.42B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.92 | $153.10 |
52-Week Low | $2.52 | $24.16 |
Enterprise Value | $348.18M | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ThredUp (TDUP) trades at $2.67, down 1.84% on the day, amid a bearish technical signal. The company reported a Q2 2026 GAAP loss of $0.05 per share, missing the expected $0.03 loss, and cut its full-year revenue outlook, citing promotional headwinds. Despite a high gross margin of 79.52%, the firm remains unprofitable with a net income margin of -6.65%. Recent news includes participation in investor conferences and the launch of a peer-to-peer marketplace, but also multiple law firm investigations into securities claims following the earnings miss.
The outlook is clouded by persistent losses and competitive pressures, though analyst consensus leans Buy (57% of 14 analysts). Key risks include execution on profitability, the sustainability of revenue growth, and potential legal overhangs. The stock's trajectory hinges on demonstrating a clear path to net income positivity amid a challenging retail environment.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
